Latest Feature

Big data and personalized medicine: Q&A with Definiens CEO Thomas Heydler

Definiens CEO Thomas Heydler discusses his ambition to position his company at the forefront of the coming revolution in personalized and predictive medicines.

The making of an icon | Dr. Tom Fogarty's obsession with innovation

Medtech icon Dr. Tom Fogarty tells about his unconventional path from upstart tinkerer in the suburbs of Cincinnati to healthcare celebrity in the heart of Silicon Valley, in Part 1 of a 3-part series.

DNA analysis in your pocket - Q&A with QuantuMDx founder Jonathan O'Halloran

QuantuMDx envisions a future where laboratory-quality diagnostics are mobile, cheap and available to everyone, from healthcare providers in developing countries to parents dealing with ill children.

Medical device tax: At least $510B paid in 2013

A analysis of reported payments for the medical device tax last year finds that 14 companies accounted for more than 97% of the nearly $500 million collected.

Breathing easier with SinuSys | MassDevice Q&A

SinuSys CEO Thomas Schreck and CMO Dr. Jerome Hester tell how they hope to replace sinus surgery with a simple, in-office procedure and how a doctor and his patient formed a company together.

Subscribe to the MassDevice
Enter your email:

Need Medtech news in a minute? We Deliver!

MassDevice +3,+5 and +7 newsletters get you caught up on all the mission critical news you need in med tech. Sign up today for our free newsletter.

Vascular Solutions lowers 2014 forecast on higher legal fees

April 24, 2014 by Arezu Sarvestani

A 32% increase in profits wasn't enough to keep Wall Street happy after Vascular Solutions missed analysts' expectations for the quarter and lowered its full-year earnings forecast.

Vascular Solutions dips again on missed Q1 earnings

Vascular Solutions (NSDQ:VASC) wasn't making friends on Wall Street this week after the company missed expectations for Q1 and lowered its forecast for the rest of the year.

Ortho shakeup: Zimmer to acquire Biomet in deal worth $13.35 billion

April 24, 2014 by Brian Johnson

Warsaw, Ind.-based orthopedic heavyweights Zimmer and Biomet agree to a merger valued at $13.35 billion.

Ortho shakeup: Zimmer to acquire Biomet in deal worth $13.35 billion

In a move that dramatically reshapes the orthopedic landscape, Zimmer (NYSE:ZMH) announced Thursday that it has agreed to acquire Biomet in a deal valued at $13.35 billion.

Spine: Baxano Surgical closes $10M private placement

April 24, 2014 by Arezu Sarvestani

Baxano Surgical puts a ribbon on a private placement funding round after raising $10 million from unnamed investors.

Spine: Baxano Surgical closes $10M private placement

Medtech tax: Scott Brown's back on the attack | On Call

April 24, 2014 by Arezu Sarvestani

New Hampshire senate candidate Scott Brown (R) returns to the medtech tax repeal fight in his new campaign, calling the levy a "money grab to fund Obamacare." On Call

MASSDEVICE ON CALL — Returning senate hopeful Scott Brown (R-N.H.) renewed his once-fervent call for repeal of the medical device tax, telling reporters during a tour of Gamma Medica that the levy is "just a money grab to fund Obamacare."

Listen to Stryker's Q1 2014 earnings call

April 23, 2014 by MassDevice staff

Officials at Stryker discuss the company's Q1 2014 earnings. The company reported profits of $70 million, or 18¢ per share, on sales of $2.31 billion for the 3 months ended March 31, for profit loss of 77% on sales growth of 5.3%.

Recall charges continue to suck up Stryker's profits

April 23, 2014 by Arezu Sarvestani

Orthopedics giant Stryker reports a 77% decline in profits in its 1st quarter, driven largely by continued charges associated with hip implant and waste management system recalls.

Recall charges take a chunk out of Stryker's bottom line in Q1

Michigan orthopedics giant Stryker (NYSE:SYK) lost a little Wall Street love today after posting 1st-quarter earnings that fell shy of analysts' expectations.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp